(Reuters) – Biogen Inc’s experimental gene therapy for a genetic retinal disease that leads to progressive vision loss did not meet the main goal of a mid-to-late stage study, the drugmaker said on Friday.
(Reporting by Mrinalika Roy in Bengaluru; Editing by Arun Koyyur)
